Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

March 10, 2022

Biotechnology

Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option

February 7, 2025
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

February 5, 2025
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

February 5, 2025
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development

February 5, 2025